Endothelial dysfunction

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Retrieved on: 
Monday, April 8, 2024
Vitamin E, Plasma, Rosuvastatin, Inflammation, Nitric oxide, Protein, EPA, Angiotensin, Endothelial dysfunction, Oxidative stress, Dietary supplement

These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.

Key Points: 
  • These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.
  • The beneficial effects of a high intensity statin and EPA on endothelial dysfunction may contribute to reduced atherothrombotic risk in outcome trials.
  • Elevated Lp(a) levels are an independent and causal risk factor for cardiovascular (CV) disease with limited treatments available.
  • The potent antioxidant actions of EPA may contribute to reduced CV events in REDUCE-IT, including among those subjects with elevated Lp(a).

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Retrieved on: 
Sunday, November 26, 2023
DREAM, Prognosis, FDA, Endothelial dysfunction, Disease, Mortality, Person, Inflammation, Ageing, ODD, Heart, Immunomodulation, Ventricular septal defect, MSB, Growth, Patient, HLHS, Journal, Heart failure, MESO, Pharmaceutical industry

Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.

Key Points: 
  • Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.
  • The FDA has authority to grant orphan drug (OD) designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition, defined as any disease or condition that affects less than 200,000 persons in the United States.
  • An orphan drug designation (ODD) qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and the potential for seven years of market exclusivity after approval.
  • A rare pediatric disease designation (RPDD) demonstrates that the disease is serious or life-threatening and the manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents, and that the disease is a rare disease or condition.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

American College of Lifestyle Medicine releases statement calling for compassionate, evidence-based lifestyle intervention as first treatment for overweight and obesity

Retrieved on: 
Thursday, April 20, 2023
Learning, Obesity, Endothelial dysfunction, Arthritis, Cancer, Type 2 diabetes, Licensure, Inflammation, Weight gain, Certification, CDC, Harvard Medical School, Hypertension, Organization, American Medical Association, ACLM, Oxidative stress, Patient, Physician, Risk, Overweight, AMA, American College, Multifactorial disease, Disease, Pharmaceutical industry, Nursing, MD

ST. LOUIS, April 20, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) has published an official position statement for the treatment of overweight and obesity, affirming the role of compassionate, evidence-based lifestyle interventions as the foundation of comprehensive treatment, with or without surgeries or medications as adjunctive therapies.

Key Points: 
  • ST. LOUIS, April 20, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) has published an official position statement for the treatment of overweight and obesity, affirming the role of compassionate, evidence-based lifestyle interventions as the foundation of comprehensive treatment, with or without surgeries or medications as adjunctive therapies.
  • "While adequately dosed lifestyle interventions may unilaterally achieve success, obesity is a complex, multifactorial disease wherein patients may require approaches beyond lifestyle alone," the statement says.
  • ACLM provides pre-professional, graduate, residency and CME/CE educational programs and curricula for physicians and other health professionals, certification in lifestyle medicine, plus lifestyle medicine practice support to members.
  • Read ACLM's full position statement for the treatment of overweight and obesity here .

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide

Retrieved on: 
Thursday, January 12, 2023
Cardiovascular disease, Therapy, Digital twin, LDL, Causality, Endothelial dysfunction, Cholesterol, Patient, PCSK9, Research, Inflammation, Atherosclerosis, LIPC, Pharmaceutical industry, Gum arabic, Causality (physics), MD

The analysis conducted by G3 Therapeutics, Aitia, and their team of scientific collaborators discovered that triglyceride-rich LDL particles appeared directly upstream from ASCAD in the Digital Twin models, suggesting causality of triglyceride-rich LDL particles.

Key Points: 
  • The analysis conducted by G3 Therapeutics, Aitia, and their team of scientific collaborators discovered that triglyceride-rich LDL particles appeared directly upstream from ASCAD in the Digital Twin models, suggesting causality of triglyceride-rich LDL particles.
  • The analysis also revealed that atherogenic lipoproteins, inflammation, and endothelial dysfunction are involved in ASCAD, lending additional credence to the novel findings.
  • "For decades, we have singularly focused on LDL-cholesterol as the sole treatment target in atherosclerotic coronary artery disease.
  • Our discovery demonstrates the power of the combination of biological big data and causal AI in bringing entirely novel treatments to our patients.

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Retrieved on: 
Tuesday, December 20, 2022
ETA, Fibrosis, IDIA, ETB, Randomized controlled trial, Moyamoya disease, Food, End organ damage, MD, American Heart Association, BP, Endothelin 1, Death, NDA, Risk, Johnson & Johnson, Patient, Science, Janssen Biotech, Aldosterone, Vascular remodelling in the embryo, US Foods, Safety, Heart failure, FDA, Hypertension, Janssen Pharmaceuticals, Obesity, Chronic kidney disease, Lancet, AHA, Blood pressure, Diabetes, Endothelial dysfunction, Hypertrophy, Kidney, Pharmaceutical industry

In the Phase 3 registration study, PRECISION, aprocitentan showed statistically significant and clinically meaningful reduction in blood pressure (BP) which was maintained for up to 48 weeks when added to combination background antihypertensive therapy in patients with resistant hypertension.

Key Points: 
  • In the Phase 3 registration study, PRECISION, aprocitentan showed statistically significant and clinically meaningful reduction in blood pressure (BP) which was maintained for up to 48 weeks when added to combination background antihypertensive therapy in patients with resistant hypertension.
  • In PRECISION, aprocitentan was generally well tolerated with no major safety concerns.
  • By targeting a currently unopposed pathophysiologic pathway, aprocitentan represents a potential novel, effective, and well-tolerated treatment for difficult-to-control hypertension.
  • Idorsia is developing aprocitentan together with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer

Retrieved on: 
Wednesday, December 7, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, LLP, American Intellectual Property Law Association, Suffolk University Law School, Massachusetts Bar Association, United States patent law, Alcon, JD, Private practice, Intellectual property, Patent, Doctor of Philosophy, Petrichor, Patient, Research, Biotechnology, Endothelial dysfunction, Molecular biology, McCarter & English, Multimedia, Texas A&M University, Boston Bar Association, Toyota Aurion, Applied Genetic Technologies Corporation, Ithaca College, McCarter, Pharmaceutical industry, Biochemistry

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.
  • View the full release here: https://www.businesswire.com/news/home/20221207005300/en/
    We are delighted to welcome Jon to Aurion Biotech, said Greg Kunst, chief executive officer.
  • In addition to his role at Aurion, Dr. Jonathan Sparks is also a partner and chair of the Intellectual Property practice at McCarter & English, LLP.
  • Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech.

Aurion Biotech Expands Its Leadership Team

Retrieved on: 
Wednesday, November 30, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, Science, Gilead Sciences, Takeda Pharmaceutical Company, Liberty University, Human services, Union, University, Multimedia, Purdue University, Seagen, Abbott Laboratories, BLA, Patient, BS, Regulatory affairs, Endothelial dysfunction, Biotechnology, Petrichor, American University, NDA, AMD, Alcon, Political science, Sherita Ceasar, Clinical trial, Pharmaceutical industry, Psychology, Biology

View the full release here: https://www.businesswire.com/news/home/20221130005132/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005132/en/
    Im delighted to welcome Sherita and Sterling to Aurion Biotech, said Greg Kunst, Aurion Biotech chief executive officer.
  • Before joining Aurion Biotech, Mr. Chung held regulatory leadership roles at Neoleukin Therapeutics, Molecular Templates, Immatics US, Seattle Genetics, Gilead Sciences, Astellas Pharmaceuticals, Takeda Pharmaceuticals, and Abbott Laboratories.
  • With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies.
  • Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech.

Aurion Biotech Wins Prestigious Prix Galien Startup Award

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Optical, Health, Wyeth, Ophthalmology, Endothelial dysfunction, Fortune 1000, CEO, The Hills Have Eyes 2, Endothelium, Physician, Alcon, Transplant, Paganini Competition, Patient, Petrichor, Multimedia, Cornea, Corneal transplantation, Digital health, Hoffmann-La Roche, Medicine, Former, Nobel Prize, Health, Pharmaceutical industry, Biotechnology, Incubator

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.
  • Aurion Biotech received the Best Start-up in Biotech / Pharma award, one of six different award categories, and was chosen from more than 146 products from 129 nominee companies, spanning 14 therapeutic areas.
  • The vetting process was rigorous: nominees are invited to apply for the Prix Galien award.
  • According to the Galien Foundation, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.